Agios Pharmaceuticals, Inc. (AGIO)

Several events impacted AGIO's stock price over the past six months. Agios reported a revenue beat in Q2 2025 but a widened net loss. The U.S. FDA reviewed the application for PYRUKYND in thalassemia. Agios posted Q3 2025 earnings, reporting an EPS of -$1.78, beating analysts' consensus estimates. Topline results from the Phase 3 RISE UP trial in Sickle Cell Disease were presented. The FDA approved AQVESME™ (mitapivat) for anemia in adults with alpha- or beta-thalassemia. Agios's cash balances were bolstered by a $200 million milestone payment from Servier and a $905 million payment from Royalty Pharma. The share price declined by 18.19% from January 10, 2025, to January 8, 2026.

Information detailing the demand seasonality for Agios Pharmaceuticals, Inc.'s products and services was not explicitly found. Demand for rare disease therapies is typically driven by disease prevalence and diagnosis rather than seasonal factors.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases, particularly genetically defined diseases and cellular metabolism. Their lead product, PYRUKYND (mitapivat), is a first-in-class pyruvate kinase (PK) activator approved for hemolytic anemia in adults with PK deficiency and anemia in adults with alpha- or beta-thalassemia. The company is also developing AG-946 for hemolytic anemias and SCD, and AG-181 for phenylketonuria (PKU).

Agios Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts, United States. Its operations and market reach extend to the US, France, Germany, Italy, Spain, and the UK.

Agios Pharmaceuticals' brand reputation has been influenced by both positive developments and challenges. Approvals for Pyrukynd have contributed positively to its reputation. However, safety concerns linked to Pyrukynd, including reported fatalities, impacted market perception, leading to a "Market Perform" rating.

Agios Pharmaceuticals, Inc. has significant institutional ownership, with 469 institutional owners and shareholders holding a total of 70,729,773 shares, accounting for 98.56% of the company. Major institutional owners include Farallon Capital Management Llc, Vanguard Group Inc, and BlackRock, Inc., among others. Individuals hold 0.96% of the company.